Q3056349 (Q3056349): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Created claim: summary (P836): 1.1.1.The virus-like particles (VLPs) are empty, non-infectious shells collected from the virus envelope protein (CP), which can be used for different purposes to solve fundamental and practical problems. Single-filter RNA (ssRNA) phase VLP is widely used for the creation of new vaccines, targeted supply of medicinal products and bioimage, however, the currently available range of SSRNA phases VLPs is small and insufficient for the further devel...) |
||||||||||||||
| Property / summary | |||||||||||||||
1.1.1.The virus-like particles (VLPs) are empty, non-infectious shells collected from the virus envelope protein (CP), which can be used for different purposes to solve fundamental and practical problems. Single-filter RNA (ssRNA) phase VLP is widely used for the creation of new vaccines, targeted supply of medicinal products and bioimage, however, the currently available range of SSRNA phases VLPs is small and insufficient for the further development of these applications. In the project we plan to produce more than 50 new VLPs from ssRNS phage CP, which have been recently identified in metagenome data. According to the differences in the characteristics of VLP candidates – production level, thermal stability and sequences – we plan to select the 5 most promising candidates for in-depth research. The selected candidates will develop effective production and purification protocols, explore VLP tolerance to genetic and chemical modifications, and define three dimensional structures. Virus-like particles, ssRNA phages, MS2, Qbeta, VLP vaccine1.1.2 Complete description of the project summary The main aim of the project is to explore the properties and applications of new particles of RNA phage-like viruses. Type of studies: Industrial research: The project is relevant to the scientific sector: 1.6 – biological knowledge; 3.4 – Medical biotechnology.The project is not related to economic activity.Information on the main project activities:•Based on the 70 RNA phase protein sequences available in the databases, the corresponding protein expression plasmamids will be created and relevant cascading proteins produced in the database•Based on the 70 RNA phage shell protein sequences will be selected the 5 prospective candidates•These Bankable VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on a low level of output and stability of the VLP.The 5 prospective candidates will be selected.The Bank’s selected VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on the two pro-denocol imputation to the GLP. The project will be launched on 1 April 2017 and completed on 31 March 2020. (English) | |||||||||||||||
| Property / summary: 1.1.1.The virus-like particles (VLPs) are empty, non-infectious shells collected from the virus envelope protein (CP), which can be used for different purposes to solve fundamental and practical problems. Single-filter RNA (ssRNA) phase VLP is widely used for the creation of new vaccines, targeted supply of medicinal products and bioimage, however, the currently available range of SSRNA phases VLPs is small and insufficient for the further development of these applications. In the project we plan to produce more than 50 new VLPs from ssRNS phage CP, which have been recently identified in metagenome data. According to the differences in the characteristics of VLP candidates – production level, thermal stability and sequences – we plan to select the 5 most promising candidates for in-depth research. The selected candidates will develop effective production and purification protocols, explore VLP tolerance to genetic and chemical modifications, and define three dimensional structures. Virus-like particles, ssRNA phages, MS2, Qbeta, VLP vaccine1.1.2 Complete description of the project summary The main aim of the project is to explore the properties and applications of new particles of RNA phage-like viruses. Type of studies: Industrial research: The project is relevant to the scientific sector: 1.6 – biological knowledge; 3.4 – Medical biotechnology.The project is not related to economic activity.Information on the main project activities:•Based on the 70 RNA phase protein sequences available in the databases, the corresponding protein expression plasmamids will be created and relevant cascading proteins produced in the database•Based on the 70 RNA phage shell protein sequences will be selected the 5 prospective candidates•These Bankable VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on a low level of output and stability of the VLP.The 5 prospective candidates will be selected.The Bank’s selected VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on the two pro-denocol imputation to the GLP. The project will be launched on 1 April 2017 and completed on 31 March 2020. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: 1.1.1.The virus-like particles (VLPs) are empty, non-infectious shells collected from the virus envelope protein (CP), which can be used for different purposes to solve fundamental and practical problems. Single-filter RNA (ssRNA) phase VLP is widely used for the creation of new vaccines, targeted supply of medicinal products and bioimage, however, the currently available range of SSRNA phases VLPs is small and insufficient for the further development of these applications. In the project we plan to produce more than 50 new VLPs from ssRNS phage CP, which have been recently identified in metagenome data. According to the differences in the characteristics of VLP candidates – production level, thermal stability and sequences – we plan to select the 5 most promising candidates for in-depth research. The selected candidates will develop effective production and purification protocols, explore VLP tolerance to genetic and chemical modifications, and define three dimensional structures. Virus-like particles, ssRNA phages, MS2, Qbeta, VLP vaccine1.1.2 Complete description of the project summary The main aim of the project is to explore the properties and applications of new particles of RNA phage-like viruses. Type of studies: Industrial research: The project is relevant to the scientific sector: 1.6 – biological knowledge; 3.4 – Medical biotechnology.The project is not related to economic activity.Information on the main project activities:•Based on the 70 RNA phase protein sequences available in the databases, the corresponding protein expression plasmamids will be created and relevant cascading proteins produced in the database•Based on the 70 RNA phage shell protein sequences will be selected the 5 prospective candidates•These Bankable VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on a low level of output and stability of the VLP.The 5 prospective candidates will be selected.The Bank’s selected VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on the two pro-denocol imputation to the GLP. The project will be launched on 1 April 2017 and completed on 31 March 2020. (English) / qualifier | |||||||||||||||
point in time: 15 July 2021
| |||||||||||||||
Revision as of 12:34, 15 July 2021
Project Q3056349 in Latvia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3056349 in Latvia |
Statements
551,326.07 Euro
0 references
648,618.91 Euro
0 references
1 April 2017
0 references
31 March 2020
0 references
Atvasināta publiska persona "Latvijas Biomedicīnas pētījumu un studiju centrs"
0 references
56°58'59.81"N, 24°1'53.44"E
0 references
1.1.1.Projekta kopsavilkuma īss apraksts Vīrusveidīgās daļiņas (Virus-like particles, VLPs) ir tukšas, neinfekciozas, no vīrusa apvalka proteīna (CP) savāktas čaulas, kuras var izmantot dažādiem mērķiem fundamentālu un praktisku problēmu risināšanai. Vienpavediena RNS (ssRNS) fāgu VLP tiek plaši pielietotas jaunu vakcīnu radīšanai, ārstniecisku preparātu mērķētai piegādei un bioattēlošani, tomēr pašreiz pieejamais ssRNS fāgu VLP klāsts ir neliels un nepietiekošs minēto pielietojumu turpmākai attīstībai. Projektā mēs plānojam uzproducēt vairāk, kā 50 jaunas VLP no ssRNS fāgu CP, kuri ir nesen identificēti metagenomu datos. Pēc VLP kandidātu īpašību – produkcijas līmeņa, termiskās stabilitātes un sekvenču atšķirībām mēs plānojam atlasīt 5 perspektīvākos kandidātus padziļinātai izpētei. Atlasītajiem kandidātiem tiks izstrādāti efektīvi producēšanas un attīrīšanas protokoli, izpētīta VLP tolerance pret ģenētiskām un ķīmiskām modifikācijām, kā arī noteiktas trīsdimensionālās struktūras.Atslēgvārdi: vīrusveidīgās daļiņas, ssRNS fāgi, MS2, Qbeta, VLP vakcīnas1.1.2.Projekta kopsavilkuma pilns aprakstsProjekta galvenais mērķis ir izpētīt jaunu RNS fāgu vīrusveidīgo daļinu īpašības un pielietojumus. Pētījumu veids: rūpnieciskais pētījums.Projekts atbilst zinātnes nozarei: 1.6 – bioloģijas zinības; 3.4 – medicīniskā biotehnoloģija.Projekts nav saistīts ar saimniecisko darbību.Informācija par galvenajām projekta darbībām:•Balstoties uz datubāzēs pieejamajām 70 RNS fāgu apvalka proteīnu sekvencēm tiks izveidotas attiecīgās proteīnu ekspresijas plazmīdas un uzproducēti attiecīgie apvalka proteīni•Balstoties uz iegūto VLP produkcijas līmeni un stabilitāti tiks atlasīti 5 perspektīvākie kandidāti•Atlasītās VLP tiks raksturotas strukturāli un pēc to tolerances inkorporēt dažādus antigēnusProjekta plānotie rezultāti ir:•vismaz divas zinātniskas publikācijas SCOPUS datubāzē iekļautos žurnālos ar citēšanas indeksu >2•deponētas 5 struktūras Proteīnu Datu Bankā (PDB)•izstrādāta tehnoloģija 5 fāgu VLP iegūšanai un attīrīšanaiProjekta kopējās attiecināmās izmaksas ir 648514€.Plānotais projekta īstenošanas ilgums ir 3 gadi. Projekts tiks uzsākts 2017. gada 1. aprīlī un pabeigts 2020. gada 31. martā. (Latvian)
0 references
1.1.1.The virus-like particles (VLPs) are empty, non-infectious shells collected from the virus envelope protein (CP), which can be used for different purposes to solve fundamental and practical problems. Single-filter RNA (ssRNA) phase VLP is widely used for the creation of new vaccines, targeted supply of medicinal products and bioimage, however, the currently available range of SSRNA phases VLPs is small and insufficient for the further development of these applications. In the project we plan to produce more than 50 new VLPs from ssRNS phage CP, which have been recently identified in metagenome data. According to the differences in the characteristics of VLP candidates – production level, thermal stability and sequences – we plan to select the 5 most promising candidates for in-depth research. The selected candidates will develop effective production and purification protocols, explore VLP tolerance to genetic and chemical modifications, and define three dimensional structures. Virus-like particles, ssRNA phages, MS2, Qbeta, VLP vaccine1.1.2 Complete description of the project summary The main aim of the project is to explore the properties and applications of new particles of RNA phage-like viruses. Type of studies: Industrial research: The project is relevant to the scientific sector: 1.6 – biological knowledge; 3.4 – Medical biotechnology.The project is not related to economic activity.Information on the main project activities:•Based on the 70 RNA phase protein sequences available in the databases, the corresponding protein expression plasmamids will be created and relevant cascading proteins produced in the database•Based on the 70 RNA phage shell protein sequences will be selected the 5 prospective candidates•These Bankable VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on a low level of output and stability of the VLP.The 5 prospective candidates will be selected.The Bank’s selected VLP will be described in the overall cost of the project, and by the structure of the project, the duration of the project is based on the two pro-denocol imputation to the GLP. The project will be launched on 1 April 2017 and completed on 31 March 2020. (English)
15 July 2021
0 references
Rātsupītes iela 1 k-1, Rīga, LV-1067
0 references
Identifiers
1.1.1.1/16/A/104
0 references